Medigen Biotechnology Corp. (TPEX:3176)

Medigen Biotechnology Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	976.81	1,388	2,223	2,041	2,145	2,207
Short-Term Investments	1,609	1,200	2,364	3,040	800	-
Trading Asset Securities	0.58	0.59	0.49	54.23	53.6	54.2
Cash & Short-Term Investments	2,586	2,588	4,588	5,135	2,998	2,261
Cash Growth	-39.91%	-43.58%	-10.67%	71.28%	32.62%	146.78%
Accounts Receivable	319.61	286.07	328.89	398.31	800.22	151.21
Other Receivables	25.58	87.61	124.72	66.37	35.46	130.51
Receivables	345.19	373.67	453.61	464.69	835.68	281.72
Inventory	676.48	645.06	546.91	692.62	752.87	323.29
Prepaid Expenses	-	22.76	33.61	382.35	99.59	-
Other Current Assets	101.81	31.36	86.4	57.93	231.96	155.9
Total Current Assets	3,710	3,661	5,708	6,733	4,918	3,022
Property, Plant & Equipment	1,955	1,981	2,043	2,198	2,189	2,166
Long-Term Investments	519.96	640.35	292.87	307.33	363.71	156.49
Goodwill	-	76.18	76.18	76.18	76.18	76.18
Other Intangible Assets	99.04	24.18	30.36	36.9	48.08	79.34
Long-Term Deferred Tax Assets	252.88	253.21	327.5	480.94	522.18	555.68
Other Long-Term Assets	81.96	74.12	49.1	150.42	81.75	97.02
Total Assets	6,618	6,710	8,527	9,982	8,199	6,152
Accounts Payable	124.32	125.29	122.57	185.01	163.94	110
Short-Term Debt	204.6	229.8	402.6	328	300	475
Current Portion of Long-Term Debt	-	47.35	1,728	28.86	21.34	21.39
Current Portion of Leases	22.1	22	17.32	13.13	3.32	3.02
Current Income Taxes Payable	20.99	12.73	24.63	22.99	-	-
Current Unearned Revenue	150.06	231.23	135	130.4	244.42	113.92
Other Current Liabilities	268.77	256.82	349.37	343.94	331.89	210.47
Total Current Liabilities	790.84	925.22	2,780	1,052	1,065	933.8
Long-Term Debt	401.86	411.25	449.1	2,129	470.77	486.37
Long-Term Leases	302.4	308	267.53	275.32	196.64	195.67
Long-Term Deferred Tax Liabilities	13.88	14.08	14.15	14.24	14.35	18.15
Other Long-Term Liabilities	13.6	10.28	10.28	29.53	15.89	7.62
Total Liabilities	1,523	1,672	3,530	3,511	1,773	1,653
Common Stock	1,393	1,393	1,393	1,394	1,394	1,390
Additional Paid-In Capital	566.46	536.79	968.14	1,562	1,109	1,101
Retained Earnings	-250.21	-352.66	-747.51	-727.98	-52.82	-631.38
Comprehensive Income & Other	-22.99	4.69	-22.45	-34.12	-54.96	-44.37
Total Common Equity	1,686	1,582	1,592	2,194	2,394	1,815
Minority Interest	3,409	3,456	3,405	4,277	4,032	2,684
Shareholders' Equity	5,095	5,038	4,997	6,471	6,426	4,499
Total Liabilities & Equity	6,618	6,710	8,527	9,982	8,199	6,152
Total Debt	930.96	1,018	2,865	2,774	992.07	1,181
Net Cash (Debt)	1,655	1,570	1,723	2,361	2,006	1,079
Net Cash Growth	15.27%	-8.86%	-27.03%	17.68%	85.87%	-
Net Cash Per Share	11.92	11.27	12.36	16.97	14.44	7.77
Filing Date Shares Outstanding	138.45	139.31	139.35	139.45	139.36	138.99
Total Common Shares Outstanding	138.45	139.31	139.35	139.45	139.36	138.99
Working Capital	2,919	2,736	2,928	5,681	3,853	2,088
Book Value Per Share	12.18	11.36	11.42	15.73	17.18	13.06
Tangible Book Value	1,587	1,482	1,485	2,081	2,270	1,660
Tangible Book Value Per Share	11.47	10.64	10.66	14.92	16.29	11.94
Land	-	330.29	330.29	354.04	354.04	354.04
Buildings	-	1,468	1,465	1,506	1,500	1,495
Machinery	-	1,233	1,266	1,240	1,178	1,002
Construction In Progress	-	2.57	21.37	14.54	4.7	17.9
Leasehold Improvements	-	9.35	3.34	3.03	2.55	1.89

Source: S&P Global Market Intelligence. Standard template. Financial Sources.